(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1533816

心臓不整脈治療薬の世界市場

Cardiac Arrhythmias Therapeutics

出版日
ページ情報
英文 183 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.05円
心臓不整脈治療薬の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心臓不整脈治療薬の世界市場は2030年までに58億米ドルに達する見込み

2023年に48億米ドルと推定される心臓不整脈治療薬の世界市場は、2023年から2030年にかけてCAGR 2.8%で成長し、2030年には58億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるナトリウムチャネル遮断薬は、CAGR 2.2%を記録し、分析期間終了時には18億米ドルに達すると予想されます。β遮断薬セグメントの成長率は、分析期間中CAGR 3.8%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 5.4％で成長予測

米国の心臓不整脈治療薬市場は2023年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは5.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9%と2.1%と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界の心臓不整脈治療薬市場- 主要動向と促進要因のまとめ

心臓不整脈治療薬には、良性のものから生命を脅かすものまでさまざまな不整脈の管理と修正を目的とした幅広い治療が含まれます。不整脈は、心拍を調節する電気信号の障害によって引き起こされ、心房細動、心室頻拍、徐脈などの状態を引き起こします。治療的介入は不整脈の種類と重症度に応じて行われ、薬物療法、生活習慣の改善、高度な医療処置が含まれます。心拍数とリズムをコントロールするために、β遮断薬、カルシウム拮抗薬、抗不整脈薬などの薬剤が処方されることが多いです。さらに重症の場合は、不整脈の原因となっている異常な心臓組織を破壊するカテーテルアブレーションや、心拍を調整するペースメーカーや除細動器などの機器の植え込みなどの処置が行われます。これらの治療は生活の質を改善するだけでなく、脳卒中や心不全などの合併症のリスクを大幅に軽減します。

心臓不整脈治療薬の進歩は、継続的な調査と技術革新によって推進されてきました。ロボット支援システムや高度な画像技術の使用を含む、より精密で効果的なアブレーション技術の開発により、これらの手技の成功率は著しく向上しました。医療機器技術の革新は、遠隔監視や患者の活動レベルに応じた自動調整など、より高度な機能を備えたペースメーカーや除細動器の開発につながった。さらに、不整脈発生に関与する特定の分子経路を標的とする新規の薬理学的薬剤の出現により、治療の新たな道が開かれました。臨床試験では、これらの新しい治療法の有効性と安全性の検討が続けられており、副作用の少ない、より効果的な不整脈管理への期待が高まっています。

心臓不整脈治療薬市場の成長は、高齢化による心血管疾患の有病率の増加、ライフスタイルの変化、不整脈の危険因子として知られる高血圧や糖尿病などの疾患の罹患率の上昇など、いくつかの要因によってもたらされます。携帯型ECGモニターやウェアラブル機器などの診断ツールの技術的進歩により、不整脈の早期かつ正確な発見が可能になり、タイムリーな介入が容易になった。消費者の行動も変化しており、患者は自分の健康についてより積極的になり、高度な治療法を求めるようになっています。さらに、ヘルスケアプロバイダーや支払者は、早期かつ効果的な不整脈管理による長期的なコストメリットをますます認識するようになり、これらの治療に対する保険適用や償還政策の改善につながった。規制環境は、新薬や新装置の承認プロセスを迅速化するなど、技術革新をより後押しするものとなっています。これらの要因が相まって、心臓不整脈治療薬市場は力強い成長と継続的な発展を遂げ、最終的には患者の予後を改善し、世界中のヘルスケアシステムにおけるこれらの疾患の負担を軽減しています。

調査対象企業の例（注目の36社）

  • Abbott Cardiovascular
  • Acesion Pharma ApS
  • Baxter International Inc.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Covis Pharma
  • Eli Lilly and Company
  • J&J MedTech
  • Mayne Pharma Group Limited
  • Medtronic
  • Novartis Pharma AG
  • Pfizer Inc
  • Roche Diagnostics Corporation
  • Upsher-Smith Laboratories, LLC
  • Viatris Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26806

Global Cardiac Arrhythmias Therapeutics Market to Reach US$5.8 Billion by 2030

The global market for Cardiac Arrhythmias Therapeutics estimated at US$4.8 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Sodium-Channel Blockers, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Beta-Blockers segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 5.4% CAGR

The Cardiac Arrhythmias Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Cardiac Arrhythmias Therapeutics Market - Key Trends and Drivers Summarized

Cardiac arrhythmias therapeutics encompass a broad range of treatments aimed at managing and correcting irregular heartbeats, which can vary from benign to life-threatening conditions. Arrhythmias are caused by disruptions in the electrical signals that regulate the heartbeat, leading to conditions such as atrial fibrillation, ventricular tachycardia, and bradycardia. Therapeutic interventions are tailored to the type and severity of the arrhythmia and may include medications, lifestyle changes, and advanced medical procedures. Medications such as beta-blockers, calcium channel blockers, and antiarrhythmic drugs are often prescribed to control the heart rate and rhythm. For more severe cases, procedures like catheter ablation, which involves destroying the abnormal heart tissue causing the arrhythmia, or the implantation of devices like pacemakers and defibrillators to regulate heartbeats are employed. These treatments not only improve quality of life but also significantly reduce the risk of complications such as stroke and heart failure.

Advancements in cardiac arrhythmias therapeutics have been propelled by ongoing research and technological innovations. The development of more precise and effective ablation techniques, including the use of robotic-assisted systems and advanced imaging technologies, has significantly improved the success rates of these procedures. Innovations in medical device technology have led to the creation of more sophisticated pacemakers and defibrillators that offer enhanced functionality, such as remote monitoring and automatic adjustment based on the patient's activity level. Additionally, the emergence of novel pharmacological agents targeting specific molecular pathways involved in arrhythmogenesis has opened new avenues for treatment. Clinical trials continue to explore the efficacy and safety of these new therapies, offering hope for more effective management of cardiac arrhythmias with fewer side effects.

The growth in the cardiac arrhythmias therapeutics market is driven by several factors, including the increasing prevalence of cardiovascular diseases due to aging populations, lifestyle changes, and rising rates of conditions such as hypertension and diabetes, which are known risk factors for arrhythmias. Technological advancements in diagnostic tools, such as portable ECG monitors and wearable devices, have enabled earlier and more accurate detection of arrhythmias, facilitating timely intervention. Consumer behavior has also shifted, with patients becoming more proactive about their health and seeking advanced treatment options. Additionally, healthcare providers and payers are increasingly recognizing the long-term cost benefits of early and effective arrhythmia management, leading to better insurance coverage and reimbursement policies for these therapies. The regulatory environment has become more supportive of innovation, with faster approval processes for new drugs and devices. Together, these factors are ensuring robust growth and continuous advancement in the cardiac arrhythmias therapeutics market, ultimately enhancing patient outcomes and reducing the burden of these conditions on healthcare systems worldwide.

Select Competitors (Total 36 Featured) -

  • Abbott Cardiovascular
  • Acesion Pharma ApS
  • Baxter International Inc.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Covis Pharma
  • Eli Lilly and Company
  • J&J MedTech
  • Mayne Pharma Group Limited
  • Medtronic
  • Novartis Pharma AG
  • Pfizer Inc
  • Roche Diagnostics Corporation
  • Upsher-Smith Laboratories, LLC
  • Viatris Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Cardiac Arrhythmias Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Heart Diseases Globally Drives Demand for Arrhythmia Therapeutics
    • Advances in Pharmacological Treatments Enhance Management of Cardiac Arrhythmias
    • Technological Innovations in Cardiac Monitoring and Diagnostic Devices Lead to Increased Disease Identification & Treatment
    • Growing Awareness of Heart Health and Preventative Care Stimulates Market Growth
    • Gene- and Cell-Based Therapies Drive Market Growth
    • Role of Digital Health and Remote Monitoring in Patient Management
    • Aging Population & Risk of Arrhythmia Represent a Demographic Driver of Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cardiac Arrhythmias Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Sodium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Sodium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Sodium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Beta-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Potassium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Potassium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Potassium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Calcium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Calcium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Calcium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION